The use of monoclonal antibody in treatment of indolent non-Hodgkin’s lymphoma

Piotr Boguradzki

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2001
vol. 5

Send email

Copy url:

abstract:

The use of monoclonal antibody in treatment of indolent non-Hodgkin’s lymphoma

Piotr Boguradzki

Współcz Onkol (2001) vol. 5, 4 (156-160)

Online publish date: 2003/07/16

View full text Get citation

Indolent non-Hodgkin’s lymphoma (iNHL) create difficult therapeutic problem. Because of insufficient effectiveness and excessive toxicity a search for new treatment modalities continues. Humanised monoclonal antibodies against surface molecules of neoplastic cells represent therapeutic alternative with distinct mechanism of action and not overlapping toxicity with cytostatic agents. They are currently used in indolent NHL as a sole treatment and in combination with cytotastics. Moreover, they are conjugated with toxins or radioisotopes to enhance their cytotoxic activity. Their additional combination with hematopoietic transplantation may soon provide a cure for indolent NHL.

keywords:

The use of monoclonal antibody in treatment of indolent non-Hodgkin’s lymphoma

Piotr Boguradzki

non-Hodgkin’s lymphoma, monoclonal antibodies, radioimmunotherapy, immunotoxins